Moomoo AI 已提取核心訊息
On December 31, 2023, Viking Global Investors LP and related entities and individuals, including Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet (collectively referred to as the Reporting Persons), filed an amendment to their Schedule 13G with the SEC, disclosing an 8.8% ownership stake in Ginkgo Bioworks Holdings, Inc. This stake amounts to 143,085,126 shares of Class A common stock. The filing indicates that the shares are beneficially owned and that the Reporting Persons have shared voting and dispositive power over these shares. The ownership percentage is based on 1,619,442,071 shares of Common Stock outstanding as of October 31, 2023, as reported by Ginkgo Bioworks in its quarterly report. The filing was made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, indicating that the shares were not acquired with the purpose or effect of changing or influencing the control of the issuer.
On December 31, 2023, Viking Global Investors LP and related entities and individuals, including Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet (collectively referred to as the Reporting Persons), filed an amendment to their Schedule 13G with the SEC, disclosing an 8.8% ownership stake in Ginkgo Bioworks Holdings, Inc. This stake amounts to 143,085,126 shares of Class A common stock. The filing indicates that the shares are beneficially owned and that the Reporting Persons have shared voting and dispositive power over these shares. The ownership percentage is based on 1,619,442,071 shares of Common Stock outstanding as of October 31, 2023, as reported by Ginkgo Bioworks in its quarterly report. The filing was made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, indicating that the shares were not acquired with the purpose or effect of changing or influencing the control of the issuer.
2023年12月31日，維京環球投資有限責任公司及相關實體和個人，包括維京環球機會母公司GP LLC、維京環球機會GP LLC、維京全球機會流動性不足投資次級有限責任公司、O. Andreas Halvorsen、David C. Ott和Rose S. Shabet（統稱爲申報人），向美國證券交易委員會提交了附表13G修正案，披露了8.8％ Ginkgo Bioworks Holdings, Inc. 的所有權。該股份相當於A類股份的143,085,126股普通股。該文件表明，這些股份是實益所有的，申報人對這些股票擁有共同的投票權和處置權。所有權百分比基於Ginkgo Bioworks在其季度報告中公佈的截至2023年10月31日已發行的1,619,442,071股普通股。該文件是根據1934年《證券交易法》第13d-1（c）條提交的，表明收購股票的目的或效果不是爲了改變或影響發行人的控制權。
2023年12月31日，維京環球投資有限責任公司及相關實體和個人，包括維京環球機會母公司GP LLC、維京環球機會GP LLC、維京全球機會流動性不足投資次級有限責任公司、O. Andreas Halvorsen、David C. Ott和Rose S. Shabet（統稱爲申報人），向美國證券交易委員會提交了附表13G修正案，披露了8.8％ Ginkgo Bioworks Holdings, Inc. 的所有權。該股份相當於A類股份的143,085,126股普通股。該文件表明，這些股份是實益所有的，申報人對這些股票擁有共同的投票權和處置權。所有權百分比基於Ginkgo Bioworks在其季度報告中公佈的截至2023年10月31日已發行的1,619,442,071股普通股。該文件是根據1934年《證券交易法》第13d-1（c）條提交的，表明收購股票的目的或效果不是爲了改變或影響發行人的控制權。
有用
沒用